scholarly journals Cognitive Training and Aerobic Exercise as Intervention Techniques for Mild Cognitive Impairment: A Research Protocol

2022 ◽  
Vol 6 (1) ◽  
pp. 1-8
Author(s):  
Harneet Cheema
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Aerobic Exercise ◽  
Cognitive Training ◽  
Research Protocol

scholarly journals Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and Cognitive Training (ACT) in Amnestic Mild Cognitive Impairment: The Blood Biomarkers Study Protocol of a Randomized Controlled Trial (The ACT Trial)

2019 ◽  
Author(s):  
Danni Li ◽  
Michelle M Mielke ◽  
W Robert Bell ◽  
Cavan Reilly ◽  
Lin Zhang ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Aerobic Exercise ◽  
Cognitive Training ◽  
Amnestic Mild Cognitive Impairment ◽  
Surrogate Endpoints ◽  
Blood Biomarkers ◽  
Effective Prevention ◽  
Randomized Controlled ◽  
Treatment Responses

Abstract Background: Alzheimer’s disease (AD) is an epidemic with tremendous public health impacts because there are currently no disease-modifying therapeutics. Randomized controlled trials (RCTs) for prevention of AD dementia often use clinical endpoints that take years to manifest (e.g., cognition) or surrogate endpoints that are costly or invasive (e.g., magnetic resonance imaging [MRI]). Blood biomarkers represent a clinically applicable alternative surrogate endpoint for RCTs that would be both cost-effective and minimally invasive, but little is known about their value as surrogate endpoints for treatment responses in the prevention of AD dementia. Methods: The objective of this study is to investigate blood neuropathological, neurodegenerative, and neurotrophic biomarkers as surrogate endpoints for treatment responses to 3 interventions in older adults with amnestic mild cognitive impairment (aMCI, a prodromal stage of AD): aerobic exercise; cognitive training; and combined aerobic exercise and cognitive training (ACT). We chose these three sets of biomarkers for their unique mechanistic associations with AD pathology, neurodegeneration and neurogenesis. This study is built on the ACT Trial (1R01AG055469), a single-blinded, multi-site, 2×2 factorial Phase II RCT that examines the synergistic effects of a 6-month ACT intervention on cognition and MRI biomarkers (AD-signature cortical thickness and hippocampal volume) (n=128). In this ACT Trial Blood Biomarkers Study, we will enroll 120 ACT Trial aMCI participants and measure blood biomarkers at baseline, 3, 6, 12 and 18 months. The goals are to: (1) Determine the effect of interventions on blood biomarkers over 6 months; (2) Evaluate blood biomarkers as surrogate endpoints for predicting cognitive responses to interventions over 18 months; and (3; exploratory) Examine blood biomarkers as surrogate endpoints for predicting brain MRI biomarker responses to interventions over 18 months. Discussion: This study aims to identify new blood biomarkers that can track cognitive decline or AD-related brain atrophy among aMCI patients subjected to a regimen of aerobic exercise and cognitive training. Findings from this study will drive the further use of blood biomarkers in developing effective prevention and treatment strategies for AD dementia. Trial registration number: This study is an ancillary study of the ACT Trial which was registered with ClinicalTrials.gov, NCT03313895.

scholarly journals Efficacy and mechanisms of combined aerobic exercise and cognitive training in mild cognitive impairment: study protocol of the ACT trial

Trials ◽  
2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Fang Yu ◽  
Feng Vankee Lin ◽  
Dereck L. Salisbury ◽  
Krupa N. Shah ◽  
Lisa Chow ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Aerobic Exercise ◽  
Cognitive Training ◽  
Study Protocol

scholarly journals Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and Cognitive Training (ACT) in Amnestic Mild Cognitive Impairment: The Blood Biomarkers Study Protocol of a Randomized Controlled Trial (The ACT Trial)

2019 ◽  
Author(s):  
Danni Li ◽  
Michelle M Mielke ◽  
W Robert Bell ◽  
Cavan Reilly ◽  
Lin Zhang ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Aerobic Exercise ◽  
Cognitive Training ◽  
Amnestic Mild Cognitive Impairment ◽  
Surrogate Endpoints ◽  
Blood Biomarkers ◽  
Effective Prevention ◽  
Randomized Controlled ◽  
Treatment Responses

Abstract Background: Alzheimer’s disease (AD) is an epidemic with tremendous public health impacts because there are currently no disease-modifying therapeutics. Randomized controlled trials (RCTs) for prevention of AD dementia often use clinical endpoints that take years to manifest (e.g., cognition) or surrogate endpoints that are costly or invasive (e.g., magnetic resonance imaging [MRI]). Blood biomarkers represent a clinically applicable alternative surrogate endpoint for RCTs that would be both cost-effective and minimally invasive, but little is known about their value as surrogate endpoints for treatment responses in the prevention of AD dementia. Methods: The objective of this study is to investigate blood neuropathological, neurodegenerative, and neurotrophic biomarkers as surrogate endpoints for treatment responses to 3 interventions in older adults with amnestic mild cognitive impairment (aMCI, a prodromal stage of AD): aerobic exercise; cognitive training; and combined aerobic exercise and cognitive training (ACT). We chose these three sets of biomarkers for their unique mechanistic associations with AD pathology, neurodegeneration and neurogenesis. This study is built on the ACT Trial (1R01AG055469), a single-blinded, multi-site, 2×2 factorial Phase II RCT that examines the synergistic effects of a 6-month ACT intervention on cognition and MRI biomarkers (AD-signature cortical thickness and hippocampal volume) (n=128). In this ACT Trial Blood Biomarkers Study, we will enroll 120 ACT Trial aMCI participants and measure blood biomarkers at baseline, 3, 6, 12 and 18 months. The goals are to: (1) Determine the effect of interventions on blood biomarkers over 6 months; (2) Evaluate blood biomarkers as surrogate endpoints for predicting cognitive responses to interventions over 18 months; and (3; exploratory) Examine blood biomarkers as surrogate endpoints for predicting brain MRI biomarker responses to interventions over 18 months. Discussion: This study aims to identify new blood biomarkers that can track cognitive decline or AD-related brain atrophy among aMCI patients subjected to a regimen of aerobic exercise and cognitive training. Findings from this study will drive the further use of blood biomarkers in developing effective prevention and treatment strategies for AD dementia. Trial registration number: This study is an ancillary study of the ACT Trial which was registered with ClinicalTrials.gov, NCT03313895.

scholarly journals Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial)

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Danni Li ◽  
Michelle M. Mielke ◽  
W. Robert Bell ◽  
Cavan Reilly ◽  
Lin Zhang ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Aerobic Exercise ◽  
Cognitive Training ◽  
Amnestic Mild Cognitive Impairment ◽  
Surrogate Endpoints ◽  
Blood Biomarkers ◽  
Effective Prevention ◽  
Randomized Controlled ◽  
Treatment Responses

Abstract Background Alzheimer’s disease (AD) is an epidemic with tremendous public health impacts because there are currently no disease-modifying therapeutics. Randomized controlled trials (RCTs) for prevention of AD dementia often use clinical endpoints that take years to manifest (e.g., cognition) or surrogate endpoints that are costly or invasive (e.g., magnetic resonance imaging [MRI]). Blood biomarkers represent a clinically applicable alternative surrogate endpoint for RCTs that would be both cost-effective and minimally invasive, but little is known about their value as surrogate endpoints for treatment responses in the prevention of AD dementia. Methods The objective of this study is to investigate blood neuropathological, neurodegenerative, and neurotrophic biomarkers as surrogate endpoints for treatment responses to three interventions in older adults with amnestic mild cognitive impairment (aMCI, a prodromal stage of AD): aerobic exercise, cognitive training, and combined aerobic exercise and cognitive training (ACT). We chose these three sets of biomarkers for their unique mechanistic associations with AD pathology, neurodegeneration and neurogenesis. This study is built on the ACT Trial (1R01AG055469), a single-blinded, multi-site, 2 × 2 factorial phase II RCT that examines the synergistic effects of a 6-month ACT intervention on cognition and MRI biomarkers (AD-signature cortical thickness and hippocampal volume) (n = 128). In this ACT Trial blood biomarkers study, we will enroll 120 ACT Trial participants with aMCI and measure blood biomarkers at baseline and at 3, 6, 12, and 18 months. The goals are to (1) determine the effect of interventions on blood biomarkers over 6 months, (2) evaluate blood biomarkers as surrogate endpoints for predicting cognitive responses to interventions over 18 months, and (3, exploratory) examine blood biomarkers as surrogate endpoints for predicting brain MRI biomarker responses to interventions over 18 months. Discussion This study aims to identify new blood biomarkers that can track cognitive decline or AD-related brain atrophy among patients with aMCI subjected to a regimen of aerobic exercise and cognitive training. Findings from this study will drive the further use of blood biomarkers in developing effective prevention and treatment strategies for AD dementia. Trial registration ClinicalTrials.gov, NCT03313895. Registered on 18 October 2017.

Neurocognitive Plasticity Is Associated with Cardiorespiratory Fitness Following Physical Exercise in Older Adults with Amnestic Mild Cognitive Impairment

2021 ◽  
pp. 1-22
Author(s):  
Galit Yogev-Seligmann ◽  
Tamir Eisenstein ◽  
Elissa Ash ◽  
Nir Giladi ◽  
Haggai Sharon ◽  
...  
Keyword(s):  
Older Adults ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Aerobic Exercise ◽  
Cardiorespiratory Fitness ◽  
Neuropsychological Tests ◽  
Aerobic Training ◽  
Amnestic Mild Cognitive Impairment ◽  
Control Group ◽  
Memory Encoding

Background: Aerobic training has been shown to promote structural and functional neurocognitive plasticity in cognitively intact older adults. However, little is known about the neuroplastic potential of aerobic exercise in individuals at risk of Alzheimer’s disease (AD) and dementia. Objective: We aimed to explore the effect of aerobic exercise intervention and cardiorespiratory fitness improvement on brain and cognitive functions in older adults with amnestic mild cognitive impairment (aMCI). Methods: 27 participants with aMCI were randomized to either aerobic training (n = 13) or balance and toning (BAT) control group (n = 14) for a 16-week intervention. Pre- and post-assessments included functional MRI experiments of brain activation during associative memory encoding and neural synchronization during complex information processing, cognitive evaluation using neuropsychological tests, and cardiorespiratory fitness assessment. Results: The aerobic group demonstrated increased frontal activity during memory encoding and increased neural synchronization in higher-order cognitive regions such as the frontal cortex and temporo-parietal junction (TPJ) following the intervention. In contrast, the BAT control group demonstrated decreased brain activity during memory encoding, primarily in occipital, temporal, and parietal areas. Increases in cardiorespiratory fitness were associated with increases in brain activation in both the left inferior frontal and precentral gyri. Furthermore, changes in cardiorespiratory fitness were also correlated with changes in performance on several neuropsychological tests. Conclusion: Aerobic exercise training may result in functional plasticity of high-order cognitive areas, especially, frontal regions, among older adults at risk of AD and dementia. Furthermore, cardiorespiratory fitness may be an important mediating factor of the observed changes in neurocognitive functions.

A Preliminary Study on the Feasibility of Using a Virtual Reality Cognitive Training Application for Remote Detection of Mild Cognitive Impairment

2017 ◽  
Vol 56 (2) ◽  
pp. 619-627 ◽  
Author(s):  
Stelios Zygouris ◽  
Konstantinos Ntovas ◽  
Dimitrios Giakoumis ◽  
Konstantinos Votis ◽  
Stefanos Doumpoulakis ◽  
...  
Keyword(s):  
Virtual Reality ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Training ◽  
Remote Detection ◽  
Preliminary Study

scholarly journals Cognitive Training Program for Thai Older People with Mild Cognitive Impairment

2016 ◽  
Vol 36 ◽  
pp. 42-45 ◽  
Author(s):  
Achiraya Chaikham ◽  
Supawadee Putthinoi ◽  
Suchitporn Lersilp ◽  
Anuruk Bunpun ◽  
Nopasit Chakpitak
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Older People ◽  
Training Program ◽  
Cognitive Training

Computerized Cognitive Training in Amnestic Mild Cognitive Impairment: A Randomized Clinical Trial

2021 ◽  
pp. 089198872110064
Author(s):  
Kevin Duff ◽  
Jian Ying ◽  
Kayla R. Suhrie ◽  
Bonnie C.A. Dalley ◽  
Taylor J. Atkinson ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Training ◽  
Computer Games ◽  
Brain Plasticity ◽  
Amnestic Mild Cognitive Impairment ◽  
Control Group ◽  
Computerized Cognitive Training ◽  
Secondary Outcomes

Objective: Computerized cognitive training has been successful in healthy older adults, but its efficacy has been mixed in patients with amnestic Mild Cognitive Impairment (MCI). Methods: In a randomized, placebo-controlled, double-blind, parallel clinical trial, we examined the short- and long-term efficacy of a brain-plasticity computerized cognitive training in 113 participants with amnestic MCI. Results: Immediately after 40-hours of training, participants in the active control group who played computer games performed better than those in the experimental group on the primary cognitive outcome (p = 0.02), which was an auditory memory/attention composite score. There were no group differences on 2 secondary outcomes (global cognitive composite and rating of daily functioning). After 1 year, there was no difference between the 2 groups on primary or secondary outcomes. No adverse events were noted. Conclusions: Although the experimental cognitive training program did not improve outcomes in those with MCI, the short-term effects of the control group should not be dismissed, which may alter treatment recommendations for these patients.

Sign in / Sign up

Export Citation Format

Share Document